TABLE 1.
Patient characteristics
| Age, years, median (range) | 54 (23–65) |
| Male sex | 22 (92) |
| Ethnicity | |
| Asian | 12 (50) |
| Caucasian | 8 (33) |
| Others | 4 (17) |
| Indication | |
| Chronic liver failure | 7 (29) |
| Acute on chronic liver failure | 3 (13) |
| Hepatocellular carcinoma | 14 (58) |
| HBeAg pretransplantation (+) | 8 (33) |
| HBV DNA pretransplantation <2.1log copies/mL | 12 (50) |
| Living donor liver transplantation | 4 (17) |
| Use of induction therapy* | 8 (33) |
| Post-transplant prednisone withdrawal time >4 months | 7 (29) |
Data presented as n (%) unless otherwise indicated.
*
Three with thymoglobulin and five with basiliximab. HBeAg Hepatitis B e antigen; HBV Hepatitis B virus